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Abstract
Background: The Glasgow Prognostic Score (GPS) is an established inflammation-based system that is used to
predict the prognosis for several types of malignancies. In this retrospective study, we assessed the postoperative
survival of 725 patients with non-metastatic esophageal squamous cell carcinoma who had normal preoperative
serum tumor marker levels according to the GPS.
Methods: Among 1394 patients who underwent esophagectomy between August 2006 and December 2010, 725
with normal preoperative serum levels of carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen
(SCC-Ag) were enrolled. All demographic, pathologic, and survival data were analyzed retrospectively. Uni- and
multivariate analyses were performed to evaluate the relationship with overall survival. The Kaplan–Meier analysis
and log-rank tests were used to compare the survival curves between patients with GPS 0 (group A) and 1 or 2
(group B).
Results: Patients in group A exhibited significantly better 3- and 5-year cancer-specific survival (CSS) rates (0.780
and 0.759, respectively) than those in group B (0.624 and 0.605, respectively). Multivariate Cox regression analysis
revealed that age, tumor length, pathological tumor-node-metastasis (pTNM) stage, venous invasion, lymph node
metastasis, serum albumin and C-reactive protein levels, and GPS were associated with postoperative survival of these
patients. Further multivariate analysis confirmed that GPS was an independent prognostic factor. The Kaplan–Meier
analysis and log-rank tests demonstrated a significant difference in CSS between groups A and B (P = 0.001).
Conclusions: GPS may be a valuable prognostic indicator for esophageal cancer patients with normal preoperative
CEA and SCC-Ag serum levels.
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survival, Glasgow Prognostic Score
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Background
Esophageal cancer is one of the most common malig-
nancies worldwide, ranking sixth in terms of cancer-
related mortality [1]. It is prevalent in China, Iran, South
Africa, Uruguay, France, and Italy. However, almost half
of new esophageal cancer cases occur in China, resulting
in the highest mortality rate [2]. Importantly, squamous
cell carcinoma, which accounts for >95 % of esophageal
cancer cases, is the major histological subtype in China
[3]. Despite improvements in less invasive treatment
strategies, surgery remains the mainstay of curative
management. Unfortunately, the outcome of surgical
resection for esophageal cancer remains poor with a
postoperative 5-year survival rate of only 20–40 % in
China [4].
Multiple tumor markers, such as carcinoembryonic
antigen (CEA) and squamous cell carcinoma antigen
(SCC-Ag), are widely used in clinical practice to estimate
the prognosis of patients with esophageal cancer. At our
institution, serum levels of CEA and SCC-Ag are rou-
tinely measured in patients with esophageal cancer prior
to treatment. However, even patients with metastatic
disease may not have elevated serum levels of CEA or
SCC-Ag before or after surgery [5–7]. Therefore, these
tumor makers cannot be applied widely for the predic-
tion of postoperative survival. On the other hand,
inflammation-based prognosis using indicators such as
the Glasgow Prognostic Score (GPS) has been shown to
be a valuable predictor of survival after surgery [8–10].
Because the GPS is thought to reflect the systemic inflam-
matory response (SIR) on the basis of hypercytokinemia
originating from the interaction between the tumor and
the host, there may be significant differences between the
prognoses made using GPS and tumor markers [11].
Therefore, we hypothesized that GPS is a useful prognos-
tic indicator of postoperative survival in patients with
esophageal cancer, especially in those who have normal
preoperative serum CEA and SCC-Ag levels. We tested
this hypothesis in a retrospective study of 725 patients
who had undergone esophagectomy due to esophageal




Among 1394 patients who underwent esophagectomy at
the Department of Thoracic Surgery of Sun Yat-sen
University Cancer Center (Guangzhou, China) between
August 2006 and December 2010, a total of 725 patients
with esophageal cancer were retrospectively enrolled in
the present study. Patients eligible for this cohort study
had pathologically confirmed esophageal squamous cell
carcinoma (ESCC). In all patients, the preoperative serum
levels of CEA and SCC-Ag were ≤5.0 ng/ml and ≤1.5 μg/l,
respectively. Each patient underwent esophagectomy.
Routine laboratory testing of serum levels of C-reactive
protein (CRP), albumin (ALB), and tumor markers, in-
cluding CEA and SCC-Ag, was performed on the day
of admission to exclude any effect associated with
interference from successive preoperative examinations
[12–15]. Patients were excluded if they had previously
received cytotoxic chemotherapy or radiotherapy or had a
past or current history of another malignancy. Patients
were not eligible if tumors were located at the cervical
esophagus or esophagogastric junction or had other histo-
logical subtypes of esophageal cancer besides ESCC. None
of the patients exhibited clinical evidence of infection or
other inflammatory conditions, and none received pre-
operative chemotherapy or irradiation. All patients were
staged according to the 7th Edition of the American Joint
Committee on Cancer (AJCC) Cancer Staging Manual.
The study protocol was approved by the Ethics Commit-
tee of Sun Yat-sen University Cancer Center.
Surgery
The standard surgical approaches consisted of the Sweet
(left thoracotomy and diaphragm incision), the McKeown
(right thoracotomy, laparotomy, and neck incision), and
the Ivor Lewis (laparotomy and right thoracotomy) proce-
dures. In our institute, the majority of patients underwent
the Sweet surgical procedure. In this cohort of patients,
thoracoabdominal lymphadenectomy was performed.
Follow-up
Patients were recommended for follow-up examinations
at our outpatient department every 3 months for the first
2 years, every 6 months during the subsequent 3 years,
and annually thereafter. Follow-up examinations consisted
of history taking, physical examination, barium esophago-
graphy, chest radiography, abdominal ultrasonography,
cervical ultrasonography, and neck-abdomen CT scans.
Patients underwent endoscopy and/or positron emission
tomography-CT, if necessary.
GPS evaluation
GPS was estimated as described previously. In brief, pa-
tients with both elevated CRP levels (>1.0 mg/dl) and
hypoalbuminemia (<3.5 g/dl) were allocated a GPS of 2.
Patients with only one of these biochemical abnormal-
ities were allocated a GPS of 1, and those with neither
abnormality were allocated a GPS of 0.
For analysis, each patient was allocated to one of two
groups: group A (GPS = 0) or group B (GPS = 1 or 2).
Patients with a GPS of 1 or 2 were combined because only
nine patients had a GPS of 2.
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Statistical analysis
Statistical analysis was performed using SPSS Statistics
18.0 software (IBM SPSS, Inc., Chicago, IL, USA). Odds
ratios (OR) with 95 % confidence intervals (95 % CIs)
were calculated by multivariate logistic regression ana-
lysis. Multivariate analysis was performed to evaluate the
influences of sex, age, maximum tumor diameter, smoking
history, history of alcohol consumption, intraoperative
blood loss, venous invasion, lymph node metastasis, serum
CRP, CEA and SCC-Ag levels, pathological tumor-node-
metastasis (pTNM) stage, and GPS on cancer-specific
survival (CSS). A two-sided P < 0.050 was considered
statistically significant.
The most valuable prognostic factors identified by uni-
variate analysis were confirmed by multivariate analysis.
Multivariate Cox regression analysis was used to exclude
other confounding factors affecting survival. The selected
variable with univariate analysis was P < 0.05. Similarly,
Kaplan–Meier analysis and the log-rank tests were used to
compare survival curves between groups. Cases were cen-
sored at death or the end of follow-up.
Results
Of the 725 enrolled patients, 539 (74.3 %) were males
and 186 (25.7 %) were females, with an age range from 32
to 80 years (median, 58 years). The mean time from the
operation to the last censoring date was 28 months. There
were no significant differences between groups A and B in
terms of most patient characteristics, with the exceptions
of the age (P = 0.019) and tumor length (P < 0.01), as
shown in Table 1.
To facilitate our analysis, the patients with a GPS of 1
or 2 were combined as a single group (group B) because
only nine patients had a GPS of 2. Group A (GPS = 0)
comprised 616 patients, and group B (GPS = 1 or 2)
comprised 109 patients. Our results indicated that can-
cer-specific survival (CSS) in group A was significantly
higher than that in group B (P = 0.001; Fig. 1). Patients in
group A exhibited significantly better 3- and 5-year
survival rates (0.780 and 0.759, respectively) than those
in group B (0.624 and 0.605, respectively).
Univariate and multivariate analyses were performed
to identify correlations between clinical characteristics
and CSS. As shown in Table 2, univariate analyses indi-
cated that the following clinical characteristics were sig-
nificant prognostic factors for CSS in patients with
esophageal cancer: age [hazard risk (HR) = 1.594; 95 %
CI = 1.030–2.467; P = 0.036]; tumor length (HR = 1.477;
95 % CI = 1.085–2.011; P < 0.013); pTNM stage (HR =
2.511; 95 % CI = 1.966–3.208; P < 0.001); venous invasion
(HR = 2.984; 95 % CI 1.466–6.072; P = 0.003); lymph node
metastasis (HR = 2.614; 95 % CI = 1.941–3.519; P < 0.001);
serum levels of ALB (HR = 3.905; 95 % CI = 1.919–7.945;
P < 0.001); CRP (HR = 1.751; 95 % CI = 1.239–2.473;
P = 0.001); and GPS (HR = 0.555; 95 % CI = 0.395–
0.779; P = 0.001).Further multivariate analysis based
on the previously mentioned parameters confirmed that
only pTNM stage (HR = 2.419; 95 % CI = 1.892–3.094;
P < 0.001), venous invasion (HR = 2.462; 95 % CI = 1.207–
5.032; P = 0.013), and GPS (HR = 1.625; 95 % CI = 1.155–
2.286; P = 0.005) were independent prognostic factors
(Table 3). Our study revealed that GPS, measured at
admission prior to treatment, is a useful predictor of
postoperative outcome in this group of patients.
Discussion
The prognosis for esophageal carcinoma patients is in-
fluenced by various pathological characteristics. The
tumor markers CEA, SCC-Ag, CA19-9, and CYFRA
Table 1 Baseline characteristics of patients grouped according
to the Glasgow Prognostic Score
Characteristic Group A Group B P
(n = 616, 85 %) (n = 109, 15 %) (χ2 test)
Age (years)
≤65 564 (77.79 %) 92 (12.69 %)
>65 52 (7.17 %) 17 (2.34 %) 0.019
Sex
Male 452 (62.34 %) 87 (12.00 %)
Female 164 (22.62 %) 22 (3.03 %) 0.156
Smoking history
Yes 377 (52.00 %) 75 (10.34 %)
No 239 (32.97 %) 34 (4.69 %) 0.131
History of alcohol
consumption
Yes 205 (28.28 %) 45 (6.21 %) 0.091
No 411 (56.69 %) 63 (8.69 %)
Tumor length (cm)
≤5 474 (65.38 %) 52 (7.17 %) <0.001
>5 132 (18.21 %) 57 (7.86 %)
Intraoperative blood loss (ml)
≤200 471 (64.97 %) 77 (10.62 %)
>200 143 (19.72 %) 31 (4.28 %) 0.225
pTNM stage
I 92 (12.69 %) 11 (1.52 %)
II 299 (41.24 %) 46 (6.34 %)
III 225 (31.03 %) 52 (7.17 %) 0.069
Venous invasion
Absence 603 (83.17 %) 107 (14.76 %)
Presence 13 (1.79 %) 2 (0.28 %) 0.852
Lymph node metastasis
Absence 332 (45.79 %) 56 (7.72 %)
Presence 284 (39.17 %) 53 (7.31 %) 0.627
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21-1 are commonly used to estimate the preoperative
tumor status as well as postoperative survival and re-
currence in patients with esophageal cancer [5, 6, 16].
Before 2010, the serum levels of CEA and SCC-Ag
were measured routinely prior to treatment in all pa-
tients at our institution. Therefore, CEA and SCC-Ag
were adopted as the two prognostic markers in the
present study. However, many patients with metastatic
disease may not have elevated CEA or SCC-Ag serum
levels before or after surgery [5–7]. This study was
undertaken to investigate whether GPS, measured prior to
treatment, is useful in predicting the postoperative survival
of patients with esophageal cancer who have normal pre-
operative serum CEA and SCC-Ag levels. Of interest,
multivariate analyses revealed that GPS was associated
with postoperative survival, indicating that GPS, measured
at admission prior to treatment, is a useful predictor of
postoperative outcome.
Recently, several reports have indicated that the pres-
ence of a systemic inflammatory response is a useful in-
dicator of outcome among patients with esophageal
cancer [17–21]. However, few studies have investigated
whether GPS is useful for predicting postoperative out-
come in ESCC patients with normal preoperative serum
CEA and SCC-Ag levels.
Fig. 1 Relationship between patient groups A and B (divided according to the Glasgow Prognostic Score (GPS) and the 5-year cancer-specific survival
(CSS). The 5-year CSS of group A (GPS = 0) was significantly higher than that of group B (GPS = 1, 2) (75.9 and 60.5 %, respectively; P = 0.001)
Table 2 Univariate analysis of factors related to esophageal
cancer survival
Characteristic P HR 95 % CI for Exp(B)
Lower Upper
Age (≤65 or >65 years) 0.036 1.594 1.030 2.467
Sex (male or female) 0.072 0.732 0.521 1.028
Smoking history 0.164 1.238 0.917 1.672
History of alcohol consumption (ml) 0.311 1.164 0.868 1.562
Tumor length (cm) 0.013 1.477 1.085 2.011
Intraoperative blood loss (ml) 0.124 1.279 0.935 1.751
pTNM stage <0.001 2.511 1.966 3.208
Venous invasion 0.003 2.984 1.466 6.072
Lymph node metastasis <0.001 2.614 1.941 3.519
Albumin (g/l) <0.001 3.905 1.919 7.945
CRP (mg/l) 0.001 1.751 1.239 2.473
CEA (ng/ml) 0.070 1.126 0.990 1.281
SCC (μg/l) 0.376 1.176 0.822 1.682
GPS 0.001 0.555 0.395 0.779
Table 3 Multivariate analysis of selected clinical characteristics
in relation to overall survival
Characteristic P HR 95 % CI for Exp(B)
Lower Upper
Age (years) 0.068 1.732 1.118 2.684
Tumor length (cm) 0.836 1.339 0.981 1.828
pTNM stage <0.001 2.419 1.892 3.094
Venous invasion 0.013 2.462 1.207 5.032
Lymph node metastasis 0.339 2.577 1.910 3.477
GPS 0.005 1.625 1.155 2.286
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The causal relationship between GPS and cancer survival
may be due to the presence of a systemic inflammatory re-
sponse and the influence of the associated nutritional de-
cline [22, 23]. GPS may reflect hypercytokinemia resulting
from immune cell activation as part of tumor versus host
response, which may differ from the mechanism of tumor
progression indicated by tumor marker levels [24, 25]. Due
to the presence of cachexia caused by SIR-induced hypercy-
tokinemia, patients in group B were expected to exhibit
fewer clinical characteristics on the basis of nutritional sta-
tus, neutrophil/lymphocyte ratio, and serum ALB level than
those in group A.
As mentioned previously, GPS appears to be a signifi-
cant prognostic factor that can be used to facilitate an
accurate estimation of tumor characteristics in select
populations. The results of our study showed that CSS
of group A was superior to that of group B. Interestingly,
univariate analysis identified two types of clinical character-
istics as significant prognostic factors for CSS in patients
with esophageal cancer: tumor-related characteristics, such
as lymph node metastasis, tumor length, venous invasion,
lymph node metastasis and pTNM stage (I, II, and III), and
SIR-related characteristics, such as the serum levels of ALB
and CRP and the GPS (0/1, 2) [26]. It is well-known
that the latter three indicators are associated with
hypercytokinemia. Moreover, among the clinical charac-
teristics identified in the univariate analysis, multivariate
analysis clearly demonstrated that the inflammation-based
prognostic indicator GPS was associated with CSS. Al-
though there were three SIR-related characteristics which
were associated with CSS, Kaplan–Meier analysis revealed
that patients could be divided into two independent
groups on the basis of GPS (GPS 0/1, 2).
Conclusions
The levels of CRP, albumin, CEA, SCC-Ag, and other
serum indexes are routinely measured in patients. Con-
sequently, it is simple to evaluate the GPS for each
patient prior to treatment. Thus, the pretreatment GPS
is an easily measurable and valuable preoperative prog-
nostic indicator for esophageal cancer patients with
normal preoperative CEA and SCC-Ag serum levels.
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